Ecuphar Veterinaria SLU (Animalcare Group), Avgda. Río de Janeiro 60 - 66, planta 13, Barcelona, Spain.
Servei d'Estadística Aplicada, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
Vet Rec. 2022 Sep;191(6):e949. doi: 10.1002/vetr.949. Epub 2021 Sep 29.
Enflicoxib is a new COX-2 selective NSAID intended for the treatment of pain and inflammation associated with canine osteoarthritis.
A prospective, multisite, blinded, randomised, controlled, parallel-group field study was performed to determine the efficacy and safety of enflicoxib in canine osteoarthritis. A total of 242 dogs were randomised to receive enflicoxib at 4 or 2 mg/kg, mavacoxib at 2 mg/kg or placebo, orally. Enflicoxib and placebo were administered once weekly from day 0 to day 35. Mavacoxib was administered on D0 and day 14. Veterinarians assessed efficacy with a numerical rating scale and owners used the Canine Brief Pain Inventory.
After 6 weeks, enflicoxib at 4 mg/kg showed the highest percentage of responders as assessed by the veterinarians (68%) and the owners (84%), followed by mavacoxib (62and 83%, respectively), and enflicoxib at 2 mg/kg (57 and 80%, respectively). All treatments reached statistical significance versus placebo, which obtained success rates of 37% and 53%, respectively. No differences in the incidence of adverse reactions were detected among the different groups.
Enflicoxib administered weekly for 6 weeks, at 4 mg/kg PO with an initial loading dose of 8 mg/kg, is efficacious and safe for the treatment of canine osteoarthritis.
恩氟昔布是一种新型 COX-2 选择性 NSAID，旨在治疗犬骨关节炎相关的疼痛和炎症。
进行了一项前瞻性、多中心、双盲、随机、对照、平行组现场研究，以确定恩氟昔布在犬骨关节炎中的疗效和安全性。共有 242 只狗被随机分配接受恩氟昔布 4 或 2mg/kg、马昔康 2mg/kg 或安慰剂，口服。恩氟昔布和安慰剂从第 0 天到第 35 天每周给药一次。马昔康在第 0 天和第 14 天给药。兽医使用数字评分量表评估疗效，主人使用犬简明疼痛量表。
6 周后，兽医评估（68%）和主人评估（84%）显示，4mg/kg 剂量的恩氟昔布应答率最高，其次是马昔康（分别为 62%和 83%）和 2mg/kg 剂量的恩氟昔布（分别为 57%和 80%）。所有治疗方法与安慰剂相比均达到统计学意义，安慰剂的成功率分别为 37%和 53%。各组之间未发现不良反应发生率的差异。
每周口服 6 周，初始负荷剂量为 8mg/kg，4mg/kg 剂量的恩氟昔布治疗犬骨关节炎有效且安全。
